S&P Futures
6,012.75 +25.75 (+0.43%) Dow Futures
44,643.00 +248.00 (+0.56%) Nasdaq Futures
20,954.00 +104.25 (+0.50%) Russell 2000 Futures
2,436.50 +22.90 (+0.95%) Crude Oil
71.01 -0.23 (-0.32%) Gold
2,675.50 -36.70 (-1.35%)
Vir Biotechnology, Inc. (VIR)
After hours:
Vir Biotechnology, Inc.
1800 Owens Street
Suite 900
San Francisco, CA 94158
United States
415 906 4324
https://www.vir.bio
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 587
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Marianne De Backer M.B.A., M.Sc., Ph.D. | CEO & Director | 4.47M | N/A | 1969 |
| Dr. Ann M. Hanly Ph.D. | Executive VP & Chief Technology Officer | 896.07k | N/A | 1970 |
| Dr. Jeff Calcagno M.D. | Executive VP & Chief Business Officer | 860.49k | N/A | 1961 |
| Dr. Klaus Frueh Ph.D. | Co-Founder & Scientific Advisor | 177.66k | N/A | 1960 |
| Dr. Lawrence Corey M.D. | Co-Founder & Scientific Advisor | N/A | N/A | 1947 |
| Dr. Louis J. Picker M.D. | Co-Founder & Scientific Advisor | N/A | N/A | N/A |
| Mr. Jason O'Byrne | Executive VP & CFO | N/A | N/A | 1968 |
| Mr. Brent Sabatini | Senior VP, Principal Accounting Officer & Chief Accounting Officer | N/A | N/A | 1974 |
| Dr. Jennifer Eileen Towne Ph.D. | Executive VP & Chief Scientific Officer | N/A | N/A | N/A |
| Ms. Heather Rowe Armstrong | Vice President of Investor Relations | N/A | N/A | N/A |
Description
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.
Corporate Governance
Vir Biotechnology, Inc.’s ISS Governance QualityScore as of November 1, 2024 is 10. The pillar scores are Audit: 4; Board: 6; Shareholder Rights: 8; Compensation: 10.
